A carregar...
Publicação
Utilização de biomarcadores para prever a resposta aos inibidores de TNF-α em pacientes com Doenças autoimunes: Uma revisão sistemática
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 12.29 MB | Adobe PDF |
Autores
Orientador(es)
Resumo(s)
As Doenças autoimunes têm uma prevalência elevada e, apesar de todos os progressos na área da saúde, continuam a ser uma causa importante de morbilidade mundialmente. Apesar do tratamento com inibidores de TNF-α ter trazido uma melhoria significativa, ainda há respostas insuficientes a estes fármacos. Assim, torna-se fundamental o estudo de biomarcadores preditivos de resposta à terapêutica, otimizando o tratamento. Avaliar os preditores de resposta aos inibidores de TNF-α em pacientes com Doenças autoimunes. Este trabalho consistiu numa revisão sistemática da literatura na base de dados PubMed. Foram incluídos estudos publicados nos últimos 10 anos que investigassem a associação entre biomarcadores e a resposta clínica aos inibidores de TNF-α. Uma comparação transversal entre doenças revela padrões de biomarcadores tanto universais como específicos. A PCR é um biomarcador transversal a várias doenças com evidência forte e consistente em todas as condições. A Calprotectina Fecal e os marcadores farmacocinéticos são altamente específicos para as DII. Apesar de haver biomarcadores "universais", é quando olhamos para os biomarcadores específicos de cada contexto que realmente obtemos valor preditivo. Portanto, não se pode definir um único biomarcador que responda ao tratamento anti-TNF-α.
Immune-inflammatory diseases have a high prevalence and, despite significant advances in healthcare, they remain a major cause of morbidity worldwide. Although treatment with TNF-α inhibitors has brought substantial improvements, a considerable proportion of patients still exhibit insufficient responses to these drugs. Therefore, the study of predictive biomarkers of therapeutic response is essential to optimize treatment strategies. Evaluate predictors of response to TNF-α inhibitors in patients with immune-inflammatory diseases. This study consisted of a systematic literature review in the PubMed database. We included studies published in the past 10 years that investigated the association between biomarkers and clinical response to TNF-α inhibitors. A cross-disease comparison reveals both universal and disease-specific biomarker patterns. C-reactive protein (CRP) emerges as a consistent and robust biomarker across multiple conditions. Fecal calprotectin and pharmacokinetic markers, however, show high specificity for inflammatory bowel diseases (IBD). Although some biomarkers may be considered “universal,” the true predictive value emerges when disease-specific biomarkers are considered. Consequently, no single biomarker can be defined as a universal predictor of response to anti-TNF-α therapy.
Immune-inflammatory diseases have a high prevalence and, despite significant advances in healthcare, they remain a major cause of morbidity worldwide. Although treatment with TNF-α inhibitors has brought substantial improvements, a considerable proportion of patients still exhibit insufficient responses to these drugs. Therefore, the study of predictive biomarkers of therapeutic response is essential to optimize treatment strategies. Evaluate predictors of response to TNF-α inhibitors in patients with immune-inflammatory diseases. This study consisted of a systematic literature review in the PubMed database. We included studies published in the past 10 years that investigated the association between biomarkers and clinical response to TNF-α inhibitors. A cross-disease comparison reveals both universal and disease-specific biomarker patterns. C-reactive protein (CRP) emerges as a consistent and robust biomarker across multiple conditions. Fecal calprotectin and pharmacokinetic markers, however, show high specificity for inflammatory bowel diseases (IBD). Although some biomarkers may be considered “universal,” the true predictive value emerges when disease-specific biomarkers are considered. Consequently, no single biomarker can be defined as a universal predictor of response to anti-TNF-α therapy.
Descrição
Palavras-chave
Biomarcadores TNF-α Doenças autoimunes Resposta terapêutica